What the changes say
- Strategy shifted toward early-stage MC4R agonists for rare obesity disorders, including hypothalamic obesity and Prader-Willi syndrome.
- Cash increased to $7.5 million and current liabilities fell to $1.8 million, but funding remains necessary.
- Vyleesi-related upside narrowed to a possible $600,000 Korean-sale milestone after Cosette settlement.
- New disclosures emphasize competition, supply-chain dependence, reimbursement, cybersecurity and commercialization execution.
What changed since the prior 10-K
New
- NewRisks Related to Our Financial Results and Need for Financing
We recognized $3,751,122 as license revenue in the Consolidated Statements of Operations for the year ended June 30, 2026. The $3,751,122 of license revenue was received in the form of non-cash debt cancellation
Operations depend on license revenue, cash and financing because product revenue requires FDA or equivalent approval and profitability remains uncertain.
- NewRisks Related to Our Financial Results and Need for Financing
We have limited experience successfully commercializing pharmaceutical products, and our experience with Vyleesi may not be indicative of our ability to successfully develop or commercialize our current or future product candidates
Apart from former Vyleesi commercialization, Palatin has not shown it can develop, obtain approval for, and commercialize current candidates.
- NewRisks Related to Our Business, Strategy, and Industry
Our business strategy is increasingly focused on the development of our MC4R agonist programs for rare obesity disorders, and these programs are at an early stage of development and may not be successful
Early-stage weekly injectable and oral MC4R agonists for rare obesity disorders may fail in development or lack differentiation.
- NewRisks Related to Our Business, Strategy, and Industry
We may not receive the contingent payment retained in connection with our settlement with Cosette relating to Vyleesi
Palatin may not receive its retained $600,000 share of Cosette’s milestone if Vyleesi is not first sold in Korea.
- NewRisks Related to Our Business, Strategy, and Industry
Geopolitical conflicts and instability could disrupt our operations, increase economic uncertainty and volatility in financial markets, and adversely affect our business, financial condition and results of operations
Geopolitical conflicts could disrupt clinical sites, contract manufacturers, suppliers, transportation, cybersecurity and capital markets.
- NewRisks Related to Our Business, Strategy, and Industry
Our MC1R product candidates, including PL8177 for the treatment of ulcerative colitis, are still in the early stages of development and remain subject to clinical testing and regulatory approval. If we are unable to successfully develop and test our product candidates, we will not be successful
MC1R candidates including PL8177 for ulcerative colitis remain exposed to failed preclinical or clinical results and regulatory rejection.
- NewRisks Related to Our Business, Strategy, and Industry
Competing products and technologies may make our product candidates less competitive or obsolete and may adversely affect the commercial potential of our development programs
Approved and investigational MC4R therapies could reach patients first or offer better efficacy, safety, dosing convenience or differentiation.
- NewRisks Related to Our Business, Strategy, and Industry
We depend on third-party manufacturers and suppliers for our product candidates, and any inability to obtain adequate supplies of materials or product candidates of acceptable quality on a timely basis could delay or adversely affect our development programs
Third-party manufacturers may fail to supply compliant materials for Palatin’s long-acting peptide and oral MC4R programs on schedule.
- NewRisks Related to Our Business, Strategy, and Industry
Changes in international trade policies, tariffs, import restrictions or other governmental actions affecting pharmaceutical products, active pharmaceutical ingredients, raw materials or other components could also increase our manufacturing costs, limit the availability of materials or disrupt our supply chain
Trade restrictions, tariffs and import controls could raise pharmaceutical manufacturing costs, limit materials and disrupt supply; limited commercial capabilities add execution risk.
- NewRisks Related to Our Business, Strategy, and Industry
Our ability to successfully commercialize any approved product candidates will depend in part on obtaining adequate pricing, coverage and reimbursement from governmental authorities, private health insurers and other third-party payers, which may be difficult to obtain or maintain
Payers may restrict coverage or reimbursement for potentially costly chronic MC4R treatments through authorization, eligibility, step-therapy or pricing controls.
- NewRisks Related to Our Business, Strategy, and Industry
We may be subject to product liability claims arising from the testing, manufacture or commercialization of our product candidates or products, which could result in substantial liabilities and adversely affect our business
Product liability claims involving trials, manufacturing defects, adverse events or commercial use could create costs exceeding Palatin’s insurance.
- NewRisks Related to Our Business, Strategy, and Industry
Cybersecurity incidents, failures of our information technology systems or those of third parties upon which we rely, or unauthorized access to or disclosure of confidential information could disrupt our operations, compromise sensitive information and adversely affect our business
Cyberattacks or failures affecting Palatin, research, manufacturing, licensing or AI/ML service providers could expose sensitive information and disrupt development.
- NewRisks Related to Our Business, Strategy, and Industry
We use artificial intelligence and machine learning technologies in certain of our research and drug discovery activities, and the use of these technologies may not produce the anticipated benefits and could expose us to additional risks
- NewRisks Related to Our Business, Strategy, and Industry
We are subject to healthcare laws and regulations, including fraud and abuse, false claims, transparency, and data privacy and security laws, and failure to comply with these laws could result in substantial penalties and adversely affect our business
- NewRisks Related to Our Business, Strategy, and Industry
We are highly dependent on our management team, scientific and technical personnel and third-party contractors, consultants and collaborators, and the loss of their services or our inability to attract and retain qualified personnel could materially and adversely affect our business
- NewRisks Related to Government Regulation
Both before and after regulatory approval, our product candidates are subject to extensive and continuing regulatory requirements, and failure to comply with these requirements could delay development, prevent or limit commercialization, or result in significant penalties
- NewRisks Related to Government Regulation
Legislative, regulatory or policy changes could increase the costs of developing or commercializing our product candidates, delay or prevent regulatory approval, or otherwise adversely affect our business
- NewRisks Related to the Ownership of Our Common Stock
The market price of our common stock has been, and is likely to continue to be, highly volatile, and investors may lose all or a substantial portion of their investment
- NewRisks Related to the Ownership of Our Common Stock
If we fail to comply with the continued listing requirements of the Nasdaq Capital Market, our common stock could be delisted, which could adversely affect the market price and liquidity of our common stock and our ability to raise capital
Dropped
- DroppedRisks Related to Our Financial Results and Need for Financing
We have a limited operating history upon which to base an investment decision
- DroppedRisks Related to Our Business, Strategy, and Industry
The commercial success of Vyleesi for HSDD is a component of our corporate strategy, but we may not receive significant milestone payments under our purchase agreement with Cosette
- DroppedRisks Related to Our Business, Strategy, and Industry
The commercial success of peptides assigned to Boehringer Ingelheim is a component of our corporate strategy, but we may not receive significant milestone payments under our agreement with Boehringer Ingelheim
- DroppedRisks Related to Our Business, Strategy, and Industry
Ongoing military conflict could cause geopolitical instability, economic uncertainty, financial markets volatility and capital markets disruption, which may adversely affect our revenue, financial condition, or results of operations
- DroppedRisks Related to Our Business, Strategy, and Industry
Competing products and technologies may make our proposed products noncompetitive
Limited operating history for assessing development and commercialization capability.
- DroppedRisks Related to Our Business, Strategy, and Industry
Production and supply of our product candidates depend on contract manufacturers over whom we have no control, with the risk that we may not have adequate supplies of our product candidates or products
- DroppedRisks Related to Our Business, Strategy, and Industry
If we are unable to establish sales and marketing capabilities within our organization or enter into and maintain agreements with third parties to market and sell our product candidates, we may be unable to generate product revenue
- DroppedRisks Related to Our Business, Strategy, and Industry
We may need to hire additional employees in order to commercialize our product candidates in the future. Any inability to manage future growth could harm our ability to commercialize our product candidates, increase our costs and adversely impact our ability to compete effectively
Uncertainty over up to $159 million in Vyleesi sales-based milestones from Cosette.
- DroppedRisks Related to Our Business, Strategy, and Industry
Our ability to achieve revenues from the sale of our products will depend, in part, on our ability to obtain adequate reimbursement from private insurers and other healthcare payers
Uncertainty over milestone payments from Boehringer Ingelheim retinal-disease peptide collaboration.
- DroppedRisks Related to Our Business, Strategy, and Industry
Even if we receive regulatory approval for our products in Europe, we may not be able to secure adequate pricing and reimbursement in Europe for us or any strategic partner to achieve profitability
Military conflicts’ potential effects on operations, revenue, financing and financial markets.
- DroppedRisks Related to Our Business, Strategy, and Industry
We may incur substantial liabilities and may be required to limit commercialization of our products in response to product liability lawsuits
- DroppedRisks Related to Our Business, Strategy, and Industry
Our internal computer systems, or those of our third-party contractors or consultants, may fail or suffer security breaches, that could result in a material disruption of our product development programs
- DroppedRisks Related to Our Business, Strategy, and Industry
We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties
- DroppedRisks Related to Our Business, Strategy, and Industry
We are highly dependent on our management team, senior staff professionals and third-party contractors and consultants, and the loss of their services could materially adversely affect our business
- DroppedRisks Related to Government Regulation
Both before and after marketing approval, our product candidates are subject to ongoing regulatory requirements and, if we fail to comply with these continuing requirements, we could be subject to a variety of sanctions and the sale of any approved commercial products could be suspended
- DroppedRisks Related to Government Regulation
In addition, varying interpretations of the data obtained for preclinical and clinical testing could delay, limit or prevent regulatory approval of a product candidate. Even if we submit an application to the FDA for marketing approval of a product candidate, it may not result in marketing approval from the FDA
Competition in inflammatory, dry-eye and ocular-inflammation markets.
- DroppedRisks Related to Government Regulation
FDA review and approval of the NDA before any commercial marketing or sale; and compliance with post-approval commitments and requirements
- DroppedRisks Related to Government Regulation
Legislative or regulatory healthcare reforms in the United States may make it more difficult and costly for us to obtain regulatory clearance or approval of any future product candidates and to produce, market and distribute our products after clearance or approval is obtained
Contract-manufacturing supply risks for bremelanotide combinations, PL8177, PL9643, PL9654 and other candidates.
- DroppedRisks Related to Government Regulation
Changes in healthcare policy could adversely affect our business
Difficulty establishing or outsourcing sales, marketing and distribution capabilities.
- DroppedRisks Related to the Ownership of Our Common Stock
Our stock price is volatile and may fluctuate in a way that is disproportionate to our operating performance and we expect it to remain volatile, which could limit investors’ ability to sell stock at a profit
Hiring and managing additional personnel needed for commercialization and growth.
- DroppedRisks Related to the Ownership of Our Common Stock
65,433 shares of common stock available for future issuance under our 2011 Stock Incentive Plan
Difficulty obtaining adequate reimbursement from insurers and other healthcare payers.
- DroppedRisks Related to the Ownership of Our Common Stock
Our common stock has been suspended from trading on the NYSE American. If we fail to regain compliance with the NYSE American listing standards, our common stock may be delisted from the NYSE American
Difficulty securing profitable pricing and reimbursement in Europe.
Reworded
- 99% rewrittenRisks Related to the Ownership of Our Common Stock
If securities or industry analysts do not publish research or publish unfavorable research about our business, our stock price and trading volume could decline
The risk now includes lower analyst estimates or price targets and views differing from investor expectations, not just discontinued coverage or downgrades.
- 98% rewrittenRisks Related to Our Financial Results and Need for Financing
We expect to incur significant expenses as we continue our development of MC4R and MC1R products. These expenses, among other things, have had and will continue to have an adverse effect on our stockholders’ equity, total assets and working capital
The disclosure now quantifies only a possible $600,000 Korean Vyleesi milestone, says it is unlikely soon, and describes the Boehringer agreement.
Was: We expect to incur significant expenses as we continue our development of MC1R and MCR products. These expenses, among other things, have had and will continue to have an adverse effect on our stockholders’ equity, total assets and working capital
- 96% rewrittenRisks Related to Government Regulation
The regulatory approval process is lengthy, expensive and uncertain, and may prevent us from obtaining the approvals that we require
The regulatory description was reorganized and now expressly lists manufacturing development, IND effectiveness and adequate controlled trials among approval steps.
- 92% rewrittenRisks Related to Our Business, Strategy, and Industry
We may be subject to claims that our employees, consultants, collaborators or other third parties with whom we work have wrongfully used or disclosed confidential information, trade secrets or other intellectual property of third parties
The scope expanded from former employees’ intellectual property to collaborators, research organizations and external AI/ML providers, while omitting explicit litigation consequences.
Was: We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers
- 61% rewrittenRisks Related to the Ownership of Our Common Stock
We are a smaller reporting company and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors
The risk now adds impaired capital-raising ability and removes the prior 838,142-share dilution figure.
- 45% rewrittenRisks Related to Our Financial Results and Need for Financing
We have a history of substantial net losses, including a net loss of $8.4 million for the year ended June 30, 2026. We expect to incur substantial net losses over the next few years, and we may never achieve or maintain profitability
Accumulated deficit rose to $467.5 million, while annual net loss fell to $8.4 million from $17.3 million.
Was: We have a history of substantial net losses, including a net loss of $17.3 million for the year ended June 30, 2025. We expect to incur substantial net losses over the next few years, and we may never achieve or maintain profitability
- 22% rewrittenRisks Related to Our Financial Results and Need for Financing
We will need additional funding, including funding to complete clinical trials for our product candidates, which may not be available on acceptable terms, if at all
Strategic emphasis shifted from MC1R ocular candidates to MC4R obesity programs; cash rose from $2.6 million to $7.5 million and current liabilities fell from $8.0 million to $1.8 million.
Was: We will need additional funding, including funding to complete clinical trials for our product candidates other than Vyleesi, which may not be available on acceptable terms, if at all
All 46 risk factors
Headings as the filing states them, in filing order.
Risks Related to Our Financial Results and Need for Financing
- 01Our management has determined that there is substantial doubt about our ability to continue as a going concern, which make it more difficult and more expensive for us to raise capital
- 02We have a history of substantial net losses, including a net loss of $8.4 million for the year ended June 30, 2026. We expect to incur substantial net losses over the next few years, and we may never achieve or maintain profitability45% rewritten
- 03We expect to incur significant expenses as we continue our development of MC4R and MC1R products. These expenses, among other things, have had and will continue to have an adverse effect on our stockholders’ equity, total assets and working capital98% rewritten
- 04We recognized $3,751,122 as license revenue in the Consolidated Statements of Operations for the year ended June 30, 2026. The $3,751,122 of license revenue was received in the form of non-cash debt cancellationNew
- 05We will need additional funding, including funding to complete clinical trials for our product candidates, which may not be available on acceptable terms, if at all22% rewritten
- 06We have limited experience successfully commercializing pharmaceutical products, and our experience with Vyleesi may not be indicative of our ability to successfully develop or commercialize our current or future product candidatesNew
- 07If we are unable to obtain regulatory approval of any of our product candidates, to successfully commercialize any products for which we receive regulatory approval or to obtain additional capital, we may not be able to recover our investment in our development efforts
- 08Raising additional capital may cause dilution to existing stockholders, restrict our operations, or require us to relinquish rights
Risks Related to Our Business, Strategy, and Industry
- 09Our business strategy is increasingly focused on the development of our MC4R agonist programs for rare obesity disorders, and these programs are at an early stage of development and may not be successfulNew
- 10We may not receive the contingent payment retained in connection with our settlement with Cosette relating to VyleesiNew
- 11Geopolitical conflicts and instability could disrupt our operations, increase economic uncertainty and volatility in financial markets, and adversely affect our business, financial condition and results of operationsNew
- 12Our MC1R product candidates, including PL8177 for the treatment of ulcerative colitis, are still in the early stages of development and remain subject to clinical testing and regulatory approval. If we are unable to successfully develop and test our product candidates, we will not be successfulNew
- 13If clinical trials for our product candidates are prolonged or delayed, we may be unable to commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any revenue from potential product sales
- 14We may not be able to secure and maintain relationships with research institutions and other organizations to conduct our clinical trials
- 15Even if our product candidates receive regulatory approval, they may never achieve market acceptance, in which case our business, financial condition and results of operations will be materially adversely affected
- 16Even if our product candidates receive regulatory approval in the United States, we may never receive approval or commercialize our products outside of the United States
- 17We may not be able to keep up with the rapid technological change in the biotechnology and pharmaceutical industries, which could make any future approved products obsolete and reduce our revenue
- 18Competing products and technologies may make our product candidates less competitive or obsolete and may adversely affect the commercial potential of our development programsNew
- 19We rely on third parties over whom we have no control to conduct preclinical studies, clinical trials and other research for our product candidates and their failure to timely perform their obligations could significantly harm our product development
- 20We depend on third-party manufacturers and suppliers for our product candidates, and any inability to obtain adequate supplies of materials or product candidates of acceptable quality on a timely basis could delay or adversely affect our development programsNew
- 21Changes in international trade policies, tariffs, import restrictions or other governmental actions affecting pharmaceutical products, active pharmaceutical ingredients, raw materials or other components could also increase our manufacturing costs, limit the availability of materials or disrupt our supply chainNew
- 22Our ability to successfully commercialize any approved product candidates will depend in part on obtaining adequate pricing, coverage and reimbursement from governmental authorities, private health insurers and other third-party payers, which may be difficult to obtain or maintainNew
- 23We may be subject to product liability claims arising from the testing, manufacture or commercialization of our product candidates or products, which could result in substantial liabilities and adversely affect our businessNew
- 24Cybersecurity incidents, failures of our information technology systems or those of third parties upon which we rely, or unauthorized access to or disclosure of confidential information could disrupt our operations, compromise sensitive information and adversely affect our businessNew
- 25We use artificial intelligence and machine learning technologies in certain of our research and drug discovery activities, and the use of these technologies may not produce the anticipated benefits and could expose us to additional risksNew
- 26We may be subject to claims that our employees, consultants, collaborators or other third parties with whom we work have wrongfully used or disclosed confidential information, trade secrets or other intellectual property of third parties92% rewritten
- 27We are subject to healthcare laws and regulations, including fraud and abuse, false claims, transparency, and data privacy and security laws, and failure to comply with these laws could result in substantial penalties and adversely affect our businessNew
- 28We are highly dependent on our management team, scientific and technical personnel and third-party contractors, consultants and collaborators, and the loss of their services or our inability to attract and retain qualified personnel could materially and adversely affect our businessNew
Risks Related to Government Regulation
- 29Both before and after regulatory approval, our product candidates are subject to extensive and continuing regulatory requirements, and failure to comply with these requirements could delay development, prevent or limit commercialization, or result in significant penaltiesNew
- 30The regulatory approval process is lengthy, expensive and uncertain, and may prevent us from obtaining the approvals that we require96% rewritten
- 31Legislative, regulatory or policy changes could increase the costs of developing or commercializing our product candidates, delay or prevent regulatory approval, or otherwise adversely affect our businessNew
Risks Related to Our Intellectual Property
- 32If we fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of our intellectual property rights would diminish
- 33We may become involved in lawsuits to protect or enforce our patents or other intellectual property or the patents of our licensors, which could be expensive and time-consuming
- 34An adverse determination of any litigation or other proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing
- 35If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed
- 36Our patent applications and the enforcement or defense of our issued patents may be impacted by the application of or changes in U.S. and foreign standards
- 37We may not be able to protect our intellectual property rights throughout the world
- 38If we are unable to keep our trade secrets confidential, our technologies and other proprietary information may be used by others to compete against us
Risks Related to the Ownership of Our Common Stock
- 39The market price of our common stock has been, and is likely to continue to be, highly volatile, and investors may lose all or a substantial portion of their investmentNew
- 40If securities or industry analysts do not publish research or publish unfavorable research about our business, our stock price and trading volume could decline99% rewritten
- 41Holders of our Series A Preferred Stock and Series D Preferred Stock may have interests different from our common stockholders
- 42Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be our stockholders’ sole source of gains
- 43Anti-takeover provisions of Delaware law and our charter documents may make potential acquisitions more difficult and could result in the entrenchment of management
- 44Our charter authorizes us to issue up to 10,000,000 shares of preferred stock and to determine the terms of those shares of stock without any further action by our stockholders. If we exercise this right, it could be more difficult for a third party to acquire a majority of our outstanding voting stock
- 45We are a smaller reporting company and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors61% rewritten
- 46If we fail to comply with the continued listing requirements of the Nasdaq Capital Market, our common stock could be delisted, which could adversely affect the market price and liquidity of our common stock and our ability to raise capitalNew
Other Palatin Technologies 10-Ks
- FY2025 10-K risk factors60 risks3 new2 dropped4 reworded
Palatin faces severe delisting risks from the NYSE American due to low stock price. The company partnered with Boehringer Ingelheim for retinal disease treatments, introducing dependency on partner milestones. Accumulated deficit reached $459.1 million with a $17.3 million net loss in fiscal 2025.
Filed Sep 23, 2025 - FY2024 10-K risk factors59 risks
Palatin Technologies faces severe going concern doubts, relying heavily on additional financing to complete clinical trials for its melanocortin receptor agonists. The company sustained a net loss of $29.7 million for fiscal 2024, bringing its accumulated deficit to $441.8 million. Operations depend entirely on third-party contract manufacturers and research organizations for product supply and trial execution.
Filed Sep 30, 2024
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.